Actos Bladder Cancer Lawsuit Update: Takeda Allegedly Hid Cancer Risks to Protect Sales, Parker Waichman LLP Recounts

Takeda hid the risk of bladder cancer with their diabetes medication Actos in order to protect company profits, said Plaintiff’s attorneys to jurors in Los Angeles state court. According to Bloomberg, the closing arguments began yesterday in the first trial over a lawsuit alleging Actos causes bladder cancer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“The evidence strongly suggests that use of Actos increases the risk of bladder cancer, and that Takeda knew these dangers but chose to not warn patients” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP.

New York, New York (PRWEB) April 16, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is keeping consumers updated about the first Actos trial underway in Los Angeles. According to a Bloomberg article published on April 16, 2013, closing arguments began yesterday in the trial weighing the lawsuit of Jack Cooper, who alleges that use of Actos caused bladder cancer (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court Los Angeles). Bloomberg reports that, in closing arguments, Cooper’s attorneys argued that Takeda found that Actos was linked to bladder cancer as early as 2004, but did not alert the U.S. Food and Drug Administration (FDA) until seven years later. Plaintiff’s attorneys also stated that the company hid the risks in order to protect company profits; Actos sales totaled to over $1.6 billion annually.

“The evidence strongly suggests that use of Actos increases the risk of bladder cancer, and that Takeda knew these dangers but chose to not warn patients” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP. “Hopefully jurors will let Takeda know that they cannot get away with failing to protect consumers who relied on their product to improve their health, not worsen it.” The national personal injury firm offers free legal advice to Actos patients who believe they were injured by their use of Actos.

Actos was approved in 1999 for Type 2 diabetes. In 2011, the FDA updated the safety label on Actos to warn that the drug may increase the risk of bladder cancer after one year of use. The warning was based on an ongoing 10-year study by Kaiser Permanente. Other studies have continued to support this association. On May 31, 2012 the British Medical Journal (BMJ) published a study showing that patients were twice as likely to get bladder cancer after taking Actos for two years. On July 3, 2012, the Canadian Medical Association Journal published a study showing that Actos use was linked to a 22 percent increased risk of developing bladder cancer.

In addition to the numerous lawsuits filed in state court, Bloomberg reports that there are some 1,200 Actos lawsuits pending in the U.S. District Court for the Western District of Louisiana as part of the multidistrict litigation (MDL) entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Judge Rebecca Doherty is presiding over the litigation. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn Contact's Google Plus